{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T18:29:21Z","timestamp":1785090561107,"version":"3.55.0"},"reference-count":48,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0205","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:09:47Z","timestamp":1752098987000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["A Case of Curative Surgery after Effective Chemotherapy for Gastric Adenocarcinoma with Enteroblastic Differentiation Accompanied by Synchronous Multiple Liver Metastases"],"prefix":"10.70352","volume":"11","author":[{"given":"Shuhei","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Akita City Hospital, Akita, Akita, Japan"},{"name":"Department of Gastroenterological Surgery, Akita University Graduate School of Medicine, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Akita City Hospital, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Akita City Hospital, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinobu","family":"Umakoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Akita City Hospital, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Sageshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Akita City Hospital, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Akita City Hospital, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1929-8479","authenticated-orcid":false,"given":"Junichi","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Akita University Graduate School of Medicine, Akita, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","unstructured":"1) Chang YC, Nagasue N, Kohno H, et al. Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol 1990; 85: 1480\u20135."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Matsunou H, Konishi F, Jalal RE, et al. Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer 1994; 73: 534\u201340.","DOI":"10.1002\/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882\u20137.","DOI":"10.1093\/annonc\/mdn403"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435\u201342.","DOI":"10.1200\/JCO.2007.13.9378"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36\u201346.","DOI":"10.1056\/NEJMoa073149"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27\u201340.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer 2016; 19: 498\u2013507.","DOI":"10.1007\/s10120-015-0497-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182\u20138.","DOI":"10.1111\/his.13975"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yamazawa S, Ushiku T, Shinozaki-Ushiku A, et al. Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol 2017; 41: 989\u201397.","DOI":"10.1097\/PAS.0000000000000869"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687\u201397.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Giuffr\u00e8 G, Ieni A, Barresi V, et al. HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 2012; 65: 237\u201341.","DOI":"10.1136\/jclinpath-2011-200345"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol 2018; 71: 600\u20137.","DOI":"10.1136\/jclinpath-2017-204928"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lawlor RT, Mafficini A, Sciammarella C, et al. Genomic characterization of hepatoid tumors: context matters. Hum Pathol 2021; 118: 30\u201341.","DOI":"10.1016\/j.humpath.2021.09.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kodera Y, Fujitani K, Fukushima N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer 2014; 17: 206\u201312.","DOI":"10.1007\/s10120-013-0299-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kinoshita T, Kinoshita T, Saiura A, et al. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg 2015; 102: 102\u20137.","DOI":"10.1002\/bjs.9684"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Markar SR, Mikhail S, Malietzis G, et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Ann Surg 2016; 263: 1092\u2013101.","DOI":"10.1097\/SLA.0000000000001542"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Oki E, Tokunaga S, Emi Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 2016; 19: 968\u201376.","DOI":"10.1007\/s10120-015-0530-z"},{"key":"18","unstructured":"18) Chang YC, Nagasue N, Abe S, et al. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 1992; 87:321\u20135."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Inoue M, Sano T, Kuchiba A, et al. Long-term results of gastrectomy for \u03b1-fetoprotein-producing gastric cancer. Br J Surg 2010; 97: 1056\u201361.","DOI":"10.1002\/bjs.7081"},{"key":"20","unstructured":"20) Makino H, Kunisaki C, Izumisawa Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 2010; 30: 2367\u201376."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235: 86\u201391.","DOI":"10.1097\/00000658-200201000-00011"},{"key":"22","unstructured":"22) Saiura A, Umekita N, Inoue S, et al. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002; 49: 1062\u20135."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sakamoto Y, Sano T, Shimada K, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534\u20139.","DOI":"10.1002\/jso.20739"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Schildberg CW, Croner R, Merkel S, et al. Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis. World J Surg 2012; 36: 872\u20138.","DOI":"10.1007\/s00268-012-1492-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Takemura N, Saiura A, Koga R, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012; 397: 951\u20137.","DOI":"10.1007\/s00423-012-0959-z"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Adachi Y, Tsuchihashi J, Shiraishi N, et al. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 2003; 65: 95\u2013101.","DOI":"10.1159\/000072332"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) He F, Fu Y, Sun Q, et al. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers. Hum Pathol 2021; 115: 37\u201346.","DOI":"10.1016\/j.humpath.2021.02.003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Li XD, Wu CP, Ji M, et al. Characteristic analysis of \u03b1-fetoprotein-producing gastric carcinoma in China. World J Surg Oncol 2013; 11: 246.","DOI":"10.1186\/1477-7819-11-246"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Liu X, Cheng Y, Sheng W, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102: 249\u201355.","DOI":"10.1002\/jso.21624"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ye MF, Tao F, Liu F, et al. Hepatoid adenocarcinoma of the stomach: a report of three cases. World J Gastroenterol 2013; 19: 4437\u201342.","DOI":"10.3748\/wjg.v19.i27.4437"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Becq A, Mateescu C, Khayat D, et al. Atypical presentation of hepatocellular carcinoma mimicking a gastric hepatoid adenocarcinoma: a case report. Medicine (Baltimore) 2015; 94: e1101.","DOI":"10.1097\/MD.0000000000001101"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Nakao S, Nakata B, Tendo M, et al. Salvage surgery after chemotherapy with S-1 plus cisplatin for \u03b1-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report. BMC Surg 2015; 15: 5.","DOI":"10.1186\/1471-2482-15-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Shen Z, Liu X, Lu B, et al. Hepatoid adenocarcinoma of the stomach: a case report of a rare type of gastric cancer. Oncol Lett 2016; 11: 1077\u201380.","DOI":"10.3892\/ol.2015.4023"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Simmet V, Noblecourt M, Liz\u00e9e T, et al. Chemotherapy of metastatic hepatoid adenocarcinoma: literature review and two case reports with cisplatin etoposide. Oncol Lett 2018; 15: 48\u201354.","DOI":"10.3892\/ol.2017.7263"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Jun C, Yamauchi S, Yube Y, et al. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer. Surg Case Rep 2023; 9: 86.","DOI":"10.1186\/s40792-023-01668-x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and \u03b1-fetoprotein-producing gastric carcinomas. Cancer Sci 2009; 100: 626\u201332.","DOI":"10.1111\/j.1349-7006.2009.01108.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Abe D, Akazawa Y, Yatagai N, et al. Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression. Virchows Arch 2023; 483: 405\u201314.","DOI":"10.1007\/s00428-023-03623-5"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 2010; 34: 533\u201340.","DOI":"10.1097\/PAS.0b013e3181d1dcdd"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol 2007; 38: 857\u201363.","DOI":"10.1016\/j.humpath.2006.10.020"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Liu X, Cheng Y, Sheng W, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol 2010; 34: 1465\u201371.","DOI":"10.1097\/PAS.0b013e3181f0a873"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Carr N. Tubulopapillary clear cell carcinoma of the stomach may be a type of pylorocardiac carcinoma. Pathology 2008; 40: 333.","DOI":"10.1080\/00313020801911561"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kinjo T, Taniguchi H, Kushima R, et al. Histologic and immunohistochemical analyses of \u03b1-fetoprotein producing cancer of the stomach. Am J Surg Pathol 2012; 36: 56\u201365.","DOI":"10.1097\/PAS.0b013e31823aafec"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Li W, Li Q, Yu Y, et al. Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma. Cancer Manag Res 2020; 12: 11113\u20139.","DOI":"10.2147\/CMAR.S276969"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Tsuruta S, Ohishi Y, Fujiwara M, et al. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist. Hum Pathol 2019; 88: 27\u201338.","DOI":"10.1016\/j.humpath.2019.03.006"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Wang Y, Wei X, Ke B, et al. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation. Histopathology 2023; 83: 631\u201346.","DOI":"10.1111\/his.14998"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: 822\u201331.","DOI":"10.1111\/j.1365-2559.2011.04012.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016; 53: 42\u201350.","DOI":"10.1016\/j.ejca.2015.09.018"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 2019; 22: 527\u201335.","DOI":"10.1007\/s10120-018-0891-1"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0205\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T04:51:22Z","timestamp":1752295882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0205\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0205","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0205"}}